Abstract Number: 0831 • ACR Convergence 2023
Two- and Three-Year Outcomes from the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study
Background/Purpose: The STOP-JIA study was designed to compare the effectiveness of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Consensus Treatment Plans (CTPs) for untreated…Abstract Number: 1823 • ACR Convergence 2023
Higher Body Mass Index and Older Age, Both of Which Are Linked to Immunothrombosis Are Associated with Improved Survival with Baricitinib Therapy in COVID-19 Pneumonia
Background/Purpose: Immunothrombosis is a critical pathological feature of fulminant COVID-19 pneumonia in which immunosuppression with common immunomodulatory agents such as corticosteroids, IL-6 receptor blockers, and…Abstract Number: 1858 • ACR Convergence 2023
How Did a Mandatory Switch Policy Influence the Uptake of Adalimumab Biosimilar and Other TNF Inhibitors?
Background/Purpose: In response to the low uptake of biosimilars, British Columbia (BC) in Canada became the first jurisdiction in North America to require patients with…Abstract Number: 2045 • ACR Convergence 2023
Treatment Response in a Cohort of Pediatric Patients with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)
Background/Purpose: Pediatric uveitis often requires systemic immunomodulatory therapy (IMT) to prevent sight-threatening complications. Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is a rare autoimmune condition caused…Abstract Number: 2054 • ACR Convergence 2023
Superiority of Adalimumab in Treating Childhood Chronic Idiopathic Uveitis: Evidence from a Multicentre Experience
Background/Purpose: Childhood Chronic Idiopathic Uveitis (cCIU) is a severe ocular condition that accounts for the 40% of all uveitis in children. Its timely and proper…Abstract Number: 0264 • ACR Convergence 2022
Reasons for Early Discontinuation of Targeted Synthetic (ts) or Biologic (b) DMARDs; Chart Review of 20,343 Drug Episodes Given to Patients with Rheumatoid Arthritis
Background/Purpose: The development, exacerbation, or unimprovement of clinical conditions during DMARD treatment may lead patients to abandon treatment before the necessary time has elapsed for…Abstract Number: 1436 • ACR Convergence 2022
Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
Background/Purpose: With increasing use of biologic disease modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) for the management of rheumatoid arthritis (RA), outcomes have…Abstract Number: 1606 • ACR Convergence 2022
An Expanded Anti-citrullinated Protein Antibody Profile Derived Using Unsupervised Machine Learning Predicts Treatment Responses to Biologic Therapies in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) treatments have advanced with the availability of biologic therapies. Despite these advances, 30-40% of patients receiving a biologic do not adequately…Abstract Number: 1679 • ACR Convergence 2022
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: Three-Year Outcomes
Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinically inactive disease (CID) in untreated polyarticular JIA…Abstract Number: 0818 • ACR Convergence 2021
Biologics Initiation in Moderate vs Severe Rheumatoid Arthritis Patients: Prospective Observational Study from a Canadian Registry
Background/Purpose: Prior studies have shown that in the real-world setting, rheumatoid arthritis (RA) patients have lower disease activity than those studied in clinical trials. However,…Abstract Number: 1217 • ACR Convergence 2021
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as the first or an alternative option to biologic disease-…Abstract Number: 1219 • ACR Convergence 2021
Machine Learning Based Prediction Model for Responses of bDMARDs in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Background/Purpose: Few studies on rheumatoid arthritis (RA) have generated machine learning models to predict biologic disease-modifying antirheumatic drugs (bDMARDs) responses; however, these studies included insufficient…Abstract Number: 1732 • ACR Convergence 2021
Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background/Purpose: The efficacy of B cell activator factor/B lymphocyte stimulator inhibitors (BAFFi/BLySi) for systemic lupus erythematosus (SLE) has been proven in clinical trials. However, it…Abstract Number: 2032 • ACR Convergence 2020
Treatment Response to Biological Disease-modifying Anti-rheumatic Drugs Is Associated with Favorable Changes of the Body Composition in Patients with Ankylosing Spondylitis
Background/Purpose: There is few data available regarding differences in body composition and its possible changes in patients with ankylosing spondylitis (AS) treated with biological disease-modifying…Abstract Number: 0227 • ACR Convergence 2020
Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors
Background/Purpose: Infections are one of the main complications among patients with rheumatoid arthritis (RA) with immunosuppressive treatment. The differences between treatments and the influence of…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »